(Q38498875)

English

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.

scientific article published on 29 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. (English)

1 reference

Europe PubMed Central

3 September 2017

Christopher J Gill

object named as

Christopher Gill

8

0 references

4

object named as

Nicola P Klein

1 reference

Europe PubMed Central

3 September 2017

Scott A Halperin

1

object named as

Scott A Halperin

1 reference

Europe PubMed Central

3 September 2017

author name string

Anil Gupta

2

1 reference

Europe PubMed Central

3 September 2017

Robert Jeanfreau

3

1 reference

Europe PubMed Central

3 September 2017

Keith Reisinger

5

1 reference

Europe PubMed Central

3 September 2017

Emmanuel Walter

6

1 reference

Europe PubMed Central

3 September 2017

Lisa Bedell

7

1 reference

Europe PubMed Central

3 September 2017

Peter M Dull

9

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

29 October 2010

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

28

1 reference

Europe PubMed Central

3 September 2017

50

1 reference

Europe PubMed Central

3 September 2017

7865-7872

1 reference

Europe PubMed Central

3 September 2017

Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Use of meningococcal vaccines in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Meningococcal C conjugate vaccine: the experience in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Meningococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Meningococcal polysaccharide-protein conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Human immunity to the meningococcus. II. Development of natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Effectiveness of a Mass Immunization Campaign Against Serogroup C Meningococcal Disease in Quebec

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Impact of meningococcal C conjugate vaccine use in Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.092

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.09.092

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38498875&oldid=1508553846"